Recent from talks
Todd Shapiro
Knowledge base stats:
Talk channels stats:
Members stats:
Todd Shapiro
Todd Shapiro is a Canadian business executive, entrepreneur and former radio broadcaster. He is the co-founder, chief executive officer and a director of Rhelion Life Sciences, formerly Red Light Holland Corp., and is chief executive officer and a director of Filament Health. Shapiro previously hosted The Todd Shapiro Show on SiriusXM Canada's Canada Laughs channel and was a regular fill-in host on TSN 1050.
Shapiro was born to a civil servant father and teacher mother in Toronto, Ontario. During his podcast, Shapiro stated that his parents provided him with a wonderful upbringing, but taught him little about business, which contributed to his decision to pursue the arts. He graduated with a sociology diploma from York University, followed by working at a heating, ventilation and air conditioning business. At age 26, Shapiro returned to school, enrolling in Seneca College's radio and television program.
Shapiro co-founded Red Light Holland Corp., a publicly traded company operating in the psychedelics sector, and has served as its chief executive officer and a director. In 2026, following Red Light Holland's acquisition of Filament Health, the company was renamed Rhelion Life Sciences Corp..
Following the acquisition, Shapiro became chief executive officer and a director of Filament Health. Filament is a psychedelic drug development company focused on naturally derived drug candidates.
Filament's intellectual-property portfolio includes 76 issued patents across 15 patent families relating to natural psilocybin and methods including extraction, purification, standardization and stabilization.
Its lead drug candidate, PEX010, is a standardized botanical psilocybin formulation developed by Filament. PEX010 has been supplied for clinical and academic research internationally.
PEX010 has been used in clinical research involving several psychiatric and neurological indications. In 2024, the Food and Drug Administration and Health Canada authorized a Phase 2 clinical trial of PEX010 for methamphetamine use disorder.
Filament has also supplied PEX010 to academic research programs in Canada and internationally. In 2026, reported research programs involving PEX010 included studies in palliative care, bipolar II depression and healthy-adult mechanism research, as well as research at the University of California, San Francisco.
Hub AI
Todd Shapiro AI simulator
(@Todd Shapiro_simulator)
Todd Shapiro
Todd Shapiro is a Canadian business executive, entrepreneur and former radio broadcaster. He is the co-founder, chief executive officer and a director of Rhelion Life Sciences, formerly Red Light Holland Corp., and is chief executive officer and a director of Filament Health. Shapiro previously hosted The Todd Shapiro Show on SiriusXM Canada's Canada Laughs channel and was a regular fill-in host on TSN 1050.
Shapiro was born to a civil servant father and teacher mother in Toronto, Ontario. During his podcast, Shapiro stated that his parents provided him with a wonderful upbringing, but taught him little about business, which contributed to his decision to pursue the arts. He graduated with a sociology diploma from York University, followed by working at a heating, ventilation and air conditioning business. At age 26, Shapiro returned to school, enrolling in Seneca College's radio and television program.
Shapiro co-founded Red Light Holland Corp., a publicly traded company operating in the psychedelics sector, and has served as its chief executive officer and a director. In 2026, following Red Light Holland's acquisition of Filament Health, the company was renamed Rhelion Life Sciences Corp..
Following the acquisition, Shapiro became chief executive officer and a director of Filament Health. Filament is a psychedelic drug development company focused on naturally derived drug candidates.
Filament's intellectual-property portfolio includes 76 issued patents across 15 patent families relating to natural psilocybin and methods including extraction, purification, standardization and stabilization.
Its lead drug candidate, PEX010, is a standardized botanical psilocybin formulation developed by Filament. PEX010 has been supplied for clinical and academic research internationally.
PEX010 has been used in clinical research involving several psychiatric and neurological indications. In 2024, the Food and Drug Administration and Health Canada authorized a Phase 2 clinical trial of PEX010 for methamphetamine use disorder.
Filament has also supplied PEX010 to academic research programs in Canada and internationally. In 2026, reported research programs involving PEX010 included studies in palliative care, bipolar II depression and healthy-adult mechanism research, as well as research at the University of California, San Francisco.